Gene Delivery
Partnership
Approach
About
News
Blog
Menu
Close
Novartis, Sarepta join Dyno’s enterprise to boldly go to new gene therapy frontier
Press
May 11, 2020
BioWorld
TOC LINK
TOC LINK
Press
Published
May 11, 2020
More like this
Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy
Events
April 28, 2025
Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy
Events
April 28, 2025
Low-N OpenFold fine-tuning improves peptide design without additional structures
Publications
NeurIPS MLSB
October 4, 2024
Low-N OpenFold fine-tuning improves peptide design without additional structures
Publications
NeurIPS MLSB
October 4, 2024
Generative design for gene therapy: An in vivo validated method
Publications
NeurIPS GenBio
October 27, 2023
Generative design for gene therapy: An in vivo validated method
Publications
NeurIPS GenBio
October 27, 2023
Challenges and opportunities of machine-guided capsid engineering for gene therapy
Publications
Cell & Gene Therapy Insights
February 26, 2019
Challenges and opportunities of machine-guided capsid engineering for gene therapy
Publications
Cell & Gene Therapy Insights
February 26, 2019
™
343 Arsenal St
Watertown, MA 02472
© Dyno 2024
Privacy Policy
Terms + Conditions